As measles cases surge to record levels in the U.S., Health and Human Services Secretary Robert F. | As measles cases surge ...

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug.

Three exercises could serve as promising alternatives to traditional insomnia treatment routes and help you sleep better, a ...

Drinking coffee may provide anti-inflammatory benefits leading to potential reductions in future risk for heart disease, ...

A new study by a Tulane University researcher casts doubt on a widely used shortcut in rectal cancer drug trials, raising concerns that some treatments may be fast-tracked for approval without ...

A new study by a Tulane University researcher casts doubt on a widely used shortcut in rectal cancer drug trials, raising ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, highlighting notable ocular toxicities and missed opportunities for dosing ...

The rate of COVID-related intensive care unit (ICU) admissions was 9.2 per 1,000 person-years among patients who received a monovalent booster and 13.3 per 1,000 person-years for patients who ...

FDA approves HIV-prevention shots thanks in part to Spokane research; Spokane-Rathdrum Aquifer improving as neighbors lose water; big tax and spending law cuts incentives for clean energy, creates ...

Your premium access has ended, but the best of Nation.Africa is still within reach. Renew now to unlock exclusive stories and in-depth features. Reclaim your full access. Click below to renew.

Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

"AstraZeneca’s AL amyloidosis drug fails to impress in Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.